Sponsor Pipeline

CellCentric Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
2
Recruiting
5
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-31 NCT07096778
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma		 Trial sites expanded: 20 -> 30 locations
Active Trials by Phase
Phase 2
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07096778 Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Multiple Myeloma Refractory Recruiting
Phase 1/2
NCT04068597 Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies Haematological Malignancy Recruiting
Disease Areas
Multiple Myeloma (2) Leukemia (1) Acute Myeloid Leukemia (AML) (1) Non-Hodgkin Lymphoma (1) Myelodysplastic Syndromes (MDS) (1)
Get alerts when CellCentric Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free